These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16468099)

  • 1. [Pharmacogenomics: principles and perspectives].
    Mahlknecht U
    Dtsch Med Wochenschr; 2006 Feb; 131(7):310-3. PubMed ID: 16468099
    [No Abstract]   [Full Text] [Related]  

  • 2. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenomics: questions and concerns.
    Mahlknecht U; Voelter-Mahlknecht S
    Curr Med Res Opin; 2005 Jul; 21(7):1041-7. PubMed ID: 16004671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [L[Prescription evaluation with the help of automatic data processing]].
    Bretschneider K; Voss H
    Z Arztl Fortbild (Jena); 1970 Apr; 64(8):405-12. PubMed ID: 5521437
    [No Abstract]   [Full Text] [Related]  

  • 5. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics Definitions and Sample Coding; Availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Apr; 73(68):19074-6. PubMed ID: 18677821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical, social and legal issues in pharmacogenomics.
    Wertz DC
    Pharmacogenomics J; 2003; 3(4):194-6. PubMed ID: 12931132
    [No Abstract]   [Full Text] [Related]  

  • 7. [The precautionary principle and medicinal products].
    Amédée-Manesme O
    Therapie; 2000; 55(6):675-9. PubMed ID: 11234462
    [No Abstract]   [Full Text] [Related]  

  • 8. Darwinism and pharmacogenomics: from 'one treatment fits all' to 'selection of the richest'?
    Voelter-Mahlknecht S; Mahlknecht U
    Trends Mol Med; 2004 May; 10(5):208-9. PubMed ID: 15121046
    [No Abstract]   [Full Text] [Related]  

  • 9. [Important that physicians perform quality assurance of drug treatment of elderly].
    Asberg KH
    Lakartidningen; 2007 Jan 10-16; 104(1-2):40-3. PubMed ID: 17323740
    [No Abstract]   [Full Text] [Related]  

  • 10. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 11. Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group.
    Bromley CM; Close S; Cohen N; Favis R; Fijal B; Gheyas F; Liu W; Lopez-Correa C; Prokop A; Singer JB; Snapir A; Tchelet A; Wang D; Goldstaub D;
    Pharmacogenomics J; 2009 Feb; 9(1):14-22. PubMed ID: 18794908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ethics, politics, and rights in pharmacogenomics].
    Bellver Capella V
    Rev Derecho Genoma Hum; 2002; (17):31-55. PubMed ID: 12703107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of preventable iatrogenic drug therapy: methodology. Round Table No 2 at Giens XIII].
    Imbs JL; Pletan Y; Spriet A
    Therapie; 1998; 53(4):365-70. PubMed ID: 9806006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
    Salerno RA; Lesko LJ
    Pharmacogenomics J; 2006; 6(2):78-81. PubMed ID: 16402087
    [No Abstract]   [Full Text] [Related]  

  • 15. A spoonful of sugar helps the medicine go down..
    Carter B
    J Child Health Care; 2004 Dec; 8(4):250-2. PubMed ID: 15507462
    [No Abstract]   [Full Text] [Related]  

  • 16. Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward.
    Kravitz RL; Bell RA
    Clin Pharmacol Ther; 2007 Oct; 82(4):360-2. PubMed ID: 17851573
    [No Abstract]   [Full Text] [Related]  

  • 17. The genomic revolution: is the real risk under-investment rather than bankrupt health care systems?
    Danzon P; Towse A
    J Health Serv Res Policy; 2000 Oct; 5(4):253-5. PubMed ID: 11184963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 19. Rx: not for the elderly.
    Gupta S
    Time; 2001 Dec; 158(27):99. PubMed ID: 11793590
    [No Abstract]   [Full Text] [Related]  

  • 20. Geriatric pharmacology, Special features of geriatric prescribing.
    Lamy PP
    Geriatrics; 1981 Dec; 36(12):41-52. PubMed ID: 6796458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.